Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
This study supports the clinical testing of both STING and NLRP3 agonists, respectively, in combination with chemotherapy to sensitize PDAC patients for ICI treatments.
Authors
- Brian Herbst (ORCID: https://orcid.org/0000-0001-9278-8541)
- Michael Wichroski (ORCID: https://orcid.org/0009-0009-2664-2347)
- Ruslan D. Novosiadly
- Sami Shoucair
- Mengni He
- Li Pan (ORCID: https://orcid.org/0000-0003-3720-5504)
- Melissa R. Lyman (ORCID: https://orcid.org/0000-0002-0091-0413)
- Keyu Li (ORCID: https://orcid.org/0000-0002-4547-4918)
- Vanessa Funes (ORCID: https://orcid.org/0000-0002-2111-2859)
- Birginia Espinoza (ORCID: https://orcid.org/0000-0002-0227-1176)
- Nan Niu (ORCID: https://orcid.org/0000-0002-2360-2384)
- Lei Zheng (ORCID: https://orcid.org/0000-0003-4163-2541)
- Jianxin Wang (ORCID: https://orcid.org/0000-0001-8621-543X)
- Jun-Ke Wang (ORCID: https://orcid.org/0000-0002-8605-3087)
- Yiping Mou
Institutions
- Zhejiang Chinese Medical University (CN)
- Bloomberg (United States) (US)
- Johns Hopkins University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Sichuan University (CN)
- Johns Hopkins Medicine (US)
- West China Hospital of Sichuan University (CN)
- Bristol-Myers Squibb (United States) (US)
- Sidney Kimmel Cancer Center (US)
- Zhejiang Provincial People's Hospital (CN)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Hangzhou Medical College (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Biomarker Research
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1186/s40364-024-00721-7
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Bristol-Myers Squibb
- Johns Hopkins University
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation